Re-analysis of public genetic data reveals a rare X-chromosomal variant associated with type 2 diabetes. by Bonàs-Guarch, Sílvia et al.
ARTICLE
Re-analysis of public genetic data reveals a rare
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The reanalysis of existing GWAS data represents a powerful and cost-effective opportunity to
gain insights into the genetics of complex diseases. By reanalyzing publicly available type 2
diabetes (T2D) genome-wide association studies (GWAS) data for 70,127 subjects, we
identify seven novel associated regions, ﬁve driven by common variants (LYPLAL1, NEUROG3,
CAMKK2, ABO, and GIP genes), one by a low-frequency (EHMT2), and one driven by a rare
variant in chromosome Xq23, rs146662057, associated with a twofold increased risk for T2D
in males. rs146662057 is located within an active enhancer associated with the expression of
Angiotensin II Receptor type 2 gene (AGTR2), a modulator of insulin sensitivity, and exhibits
allelic speciﬁc activity in muscle cells. Beyond providing insights into the genetics and
pathophysiology of T2D, these results also underscore the value of reanalyzing publicly
available data using novel genetic resources and analytical approaches.
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During the last decade, hundreds of genome-wide associa-tion studies (GWAS) have been performed with the aimof providing a better understanding of the biology of
complex diseases, improving their risk prediction, and ultimately
discovering novel therapeutic targets1. However, the majority of
the published GWAS have only reported primary ﬁndings, which
generally explain a small fraction of the estimated heritability.
To examine the missing heritability, most strategies involve
generating new genetic and clinical data. Very rarely are new
studies based on the revision and reanalysis of existing genetic
data by applying more powerful analytic techniques and resources
after the primary GWAS ﬁndings are published. These cost-
effective reanalysis strategies are now possible, given emerging
(1) data-sharing initiatives with large amounts of primary genetic
data for multiple human genetic diseases, as well as (2) new
and improved GWAS methodologies and resources. Notably,
genotype imputation with novel sequence-based reference
panels can now substantially increase the genetic resolution of
GWASs from previously genotyped data sets2, reaching good-
quality imputation of low frequency (minor allele frequency
[MAF]: 0.01 ≤MAF< 0.05) and rare variants (MAF< 0.01),
increasing the power to identify novel associations, and ﬁne
map the known ones. Moreover, the availability of publicly
available primary genetic data allows the homogeneous integra-
tion of multiple data sets from different origins providing more
accurate meta-analysis results, particularly at the low ranges
of allele frequency. Finally, the vast majority of reported GWAS
analyses omits the X chromosome, despite representing 5% of the
genome and coding for more than 1,500 genes3. The reanalysis of
publicly available data also enables interrogation of this
chromosome.
We hypothesized that a uniﬁed reanalysis of multiple
publicly available data sets, applying homogeneous standardized
quality control (QC), genotype imputation, and association
methods, as well as novel and denser sequence-based reference
panels for imputation would provide new insights into the
genetics and the pathophysiology of complex diseases. To test
this hypothesis, we focused this study on type 2 diabetes (T2D),
one of the most prevalent complex diseases for which
many GWAS have been performed during the past decade4.
These studies have allowed the identiﬁcation of more than
100 independent loci, most of them driven by common variants,
with a few exceptions5. Despite these efforts, there is still a large
fraction of genetic heritability hidden in the data, and the role of
low-frequency variants, although recently proposed to be minor6,
has still not been fully explored. The availability of large
T2D genetic data sets in combination with larger and more
comprehensive genetic variation reference panels2, provides
the opportunity to impute a signiﬁcantly increased fraction
of low-frequency and rare variants, and to study their contribu-
tion to the risk of developing this disease. This strategy also allows
us to ﬁne map known associated loci, increasing the chances
of ﬁnding causal variants and understanding their functional
impact. We therefore gathered publicly available T2D GWAS
cohorts with European ancestry, comprising a total of 13,857
T2D cases and 62,126 controls, to which we ﬁrst applied
harmonization and quality control protocols covering the
whole genome (including the X chromosome). We then perfor-
med imputation using 1000 Genomes Project (1000G)7 and
UK10K2 reference panels, followed by association testing.
By using this strategy, we identiﬁed novel associated
regions driven by common, low-frequency and rare variants,
ﬁne mapped and functionally annotated the existing and
novel ones, allowing us to describe a regulatory mechanism
disrupted by a novel rare and large-effect variant identiﬁed at the
X chromosome.
Results
Overall analysis strategy. As shown in Fig. 1, we ﬁrst gathered all
T2D case-control GWAS individual-level data that were available
through the EGA and dbGaP databases (i.e., Gene Environment-
Association Studies [GENEVA], Wellcome Trust Case Control
Consortium [WTCCC], Finland–United States Investigation of
NIDDM Genetics [FUSION], Resource for Genetic Epidemiology
Research on Aging [GERA], and Northwestern NuGENE project
[NuGENE]). We harmonized these cohorts, applied standardized
quality control procedures, and ﬁltered out low-quality variants
and samples (Methods and Supplementary Notes). After this
process, a total of 70,127 subjects (70KforT2D, 12,931 cases, and
57,196 controls, Supplementary Data 1) were retained for
downstream analysis. Each of these cohorts was then imputed to
the 1000G and UK10K reference panels using an integrative
method, which selected the results from the reference panel that
provided the highest accuracy for each variant, according to
IMPUTE2 info score (Methods). Finally, the results from each of
these cohorts were meta-analyzed (Fig. 1), obtaining a total of
15,115,281 variants with good imputation quality (IMPUTE2 info
score ≥ 0.7, MAF ≥ 0.001, and I2 heterogeneity score < 0.75),
across 12,931 T2D cases and 57,196 controls. Of these, 6,845,408
variants were common (MAF ≥ 0.05), 3,100,848 were low-
frequency (0.01 ≤MAF< 0.05), and 5,169,025 were rare
(0.001 ≤MAF< 0.01). Merging the imputation results derived
from the two reference panels substantially improved the number
of good-quality imputed variants, particularly within the low-
frequency and rare spectrum, compared to the imputation results
obtained with each of the panels separately. For example, a set of
5,169,025 rare variants with good quality was obtained after
integrating 1000G and UK10K results, while only 2,878,263 rare
variants were imputed with 1000G and 4,066,210 with UK10K
(Supplementary Fig. 1A). This strategy also allowed us to impute
1,357,753 indels with good quality (Supplementary Fig. 1B).
To take full advantage of publicly available genetic data, we
used three main meta-analytic approaches to adapt to the three
most common strategies for genetic data sharing: individual-level
genotypes, summary statistics, and single-case queries through
the Type 2 Diabetes Knowledge Portal (T2D Portal) (http://www.
type2diabetesgenetics.org/). We ﬁrst meta-analyzed all summary
statistics results from the DIAGRAM trans-ancestry meta-
analysis8 (26,488 cases and 83,964 controls), selecting 1,918,233
common variants (MAF ≥ 0.05), mostly imputed from HapMap,
with the corresponding fraction of non-overlapping samples in
our 70KforT2D set, i.e. the GERA and the NuGENE cohorts,
comprising a total of 7,522 cases and 50,446 controls (Fig. 1,
Supplementary Data 1). Second, the remaining variants
(13,197,048), which included mainly non-HapMap variants
(MAF< 0.05) or variants not tested above, were meta-analyzed
using all ﬁve cohorts from the 70KforT2D resource (Supplemen-
tary Data 1). Finally, low-frequency variants located in coding
regions and with p ≤ 1 × 10−4 were meta-analyzed using the non-
overlapping fraction of samples with the data from the T2D
Portal through the interrogation of exome array and whole-
exome sequence data from ~80,000 and ~17,000 individuals,
respectively6.
Pathway and functional enrichment analysis. To explore whe-
ther our results recapitulate the pathophysiology of T2D, we
performed gene-set enrichment analysis with all the variants with
p ≤ 1 × 10−5 using DEPICT9 (Methods). This analysis showed
enrichment of genes expressed in pancreas (ranked ﬁrst in tissue
enrichment analysis, p= 7.8 × 10−4, FDR< 0.05, Supplementary
Data 2) and cellular response to insulin stimulus (ranked second
in gene-set enrichment analysis, p = 3.9 × 10−8, FDR = 0.05,
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Supplementary Data 3, Supplementary Fig. 2, Supplementary
Fig. 3), in concordance with the current knowledge of the
molecular basis of T2D.
In addition, variant set enrichment analysis of the T2D-
associated credible sets across regulatory elements deﬁned in
isolated human pancreatic islets showed a signiﬁcant enrichment
for active regulatory enhancers (Supplementary Fig. 4), suggesting
that causal SNPs within associated regions have a regulatory
function, as previously reported10.
Fine-mapping and functional characterization of T2D loci. The
three association strategies allowed us to identify 57 genome-wide
signiﬁcant associated loci (p ≤ 5 × 10−8), of which seven were not
previously reported as associated with T2D (Table 1). The
remaining 50 loci have been previously reported and included, for
example, two low-frequency variants recently discovered in
Europeans, one located within one of the CCND2 introns
(rs76895963), and a missense variant within the PAM5 gene.
Furthermore, we conﬁrmed that the magnitude and direction of
the effect of all the associated variants (p ≤ 0.001) were highly
consistent with those reported previously (ρ = 0.92, p= 1 × 10
−248, Supplementary Fig. 5). In addition, the direction of effect
was consistent with all 139 previously reported variants, except
three that were discovered in east and south Asian populations
(Supplementary Data 4).
The high coverage of genetic variation ascertained in this study
allowed us to ﬁne-map known and novel loci, providing more
candidate causal variants for downstream functional interpreta-
tions. We constructed 99% credible variant sets11 for each of
these loci, i.e. the subset of variants that have, in aggregate, 99%
probability of containing the true causal variant for all 57 loci
(Supplementary Data 5). As an important improvement over
previous T2D genetic studies, we identiﬁed small structural
variants within the credible sets, consisting mostly of insertions
and deletions between 1 and 1,975 nucleotides. In fact, out of the
8,348 variants included within the credible sets for these loci, 927
(11.1%) were indels, of which 105 were genome-wide signiﬁcant
(Supplementary Data 6). Interestingly, by integrating imputed
results from 1000G and UK10K reference panels, we gained up to
41% of indels, which were only identiﬁed by either one of the two
reference panels, conﬁrming the advantage of integrating the
results from both reference panels. Interestingly, 15 of the 71
previously reported loci that we replicated (p ≤ 5.3 × 10−4 after
correcting for multiple testing) have an indel as the top variant,
highlighting the potential role of this type of variation in the
susceptibility for T2D. For example, within the IGF2BP2 intron, a
well-established and functionally validated locus for T2D12, we
found that 12 of the 57 variants within its 99% credible set
correspond to indels with genome-wide signiﬁcance (5.6 × 10−16
< p< 2.4 × 10−15), which collectively represented 18.4% posterior
probability of being causal.
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Fig. 1 Discovery and replication strategy. Publicly available GWAS datasets representing a total of 12,931 cases and 57,196 controls (70KforT2D) were ﬁrst
quality controlled, phased, and imputed, using 1000G and UK10K separately. For those variants that were present in the DIAGRAM trans-ethnic meta-
analysis, we used the summary statistics to meta-analyze our results with the cohorts that had no overlap with any of the cohorts included in the
DIAGRAM trans-ethnic meta-analysis. With this ﬁrst meta-analysis, we discovered four novel loci (within magenta panels). For the rest of the variants, we
meta-analyzed all the 70KforT2D data sets, which resulted in two novel loci (in blue panels). All the variants that were coding and showed a
p-value of ≤ 1 × 10−4 were tested for replication by interrogating the summary statistics in the Type 2 Diabetes Knowledge Portal (T2D Portal)
(http://www.type2diabetesgenetics.org/). This uncovered a novel low-frequency variant in the EHMT2 gene (highlighted with a green panel)
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To prioritize causal variants within all the identiﬁed associated
loci, we annotated their corresponding credible sets using the
Variant Effector Predictor (VEP) for coding variants13 (Supple-
mentary Data 7), and the Combined Annotation-Dependent
Depletion (CADD)14 and LINSIGHT15 tools for non-coding
variation (Supplementary Data 8 and 9). In addition, we tested
the effect of all variants on expression across multiple tissues by
interrogating GTEx16 and RNA-sequencing gene expression data
from pancreatic islets17.
Novel T2D-associated loci driven by common variants. Beyond
the detailed characterization of the known T2D-associated
regions, we also identiﬁed seven novel loci, among which, ﬁve
were driven by common variants with modest effect sizes (1.06<
OR< 1.12; Table 1, Fig. 2, Supplementary Fig. 6 and 7).
Within the ﬁrst novel T2D-associated locus in chromosome
1q41 (LYPLAL1-ZC3H11B, rs2820443, OR = 1.07 [1.04–1.09], p
= 2.6 × 10−8), several variants have been previously associated
with waist-to-hip ratio, height, visceral adipose fat in females,
adiponectin levels, fasting insulin, and non-alcoholic fatty liver
disease18–23. Among the genes in this locus, LYPLAL1, which
encodes for lysophospholypase-like 1, appears to be the most
likely effector gene, as it has been found to be downregulated in
mouse models of diet-induced obesity and upregulated during
adipogenesis24.
Second, a novel locus at chromosome 9q34.2 region (ABO,
rs505922, OR = 1.06 [1.04–1.09], p= 4.9 × 10−8) includes several
variants that have been previously associated with other
metabolic traits. For example, the variant rs651007, in linkage
disequilibrium (LD) with rs505922 (r2 = 0.507), has been shown
to be associated with fasting glucose25, and rs514659 (r2 with top
= 1) is associated with an increased risk for cardiometabolic
disorders26. One of the variants within the credible set was the
single base-pair frame-shift deletion deﬁning the blood group
O27. In concordance with previous results that linked O blood
type with a lower risk of developing T2D28, the frame-shift
deletion determining the blood group type O was associated with
a protective effect for T2D in our study (rs8176719, p = 3.4 × 10−4,
OR = 0.95 [0.91–0.98]). In addition, several variants within this
credible set are associated with the expression of the ABO gene in
multiple tissues including skeletal muscle, adipose tissue, and
pancreatic islets (Supplementary Data 9, Supplementary Data 10).
Third, a novel locus at chromosome 10q22.1 locus (NEUROG3/
COL13A1/RPL5P26, rs2642587, OR = 1.12 [1.08–1.16], p= 8.4 ×
10−9) includes NEUROG3 (Neurogenin3), which is an essential
regulator of pancreatic endocrine cell differentiation29. Mutations
in this gene have been reported to cause permanent neonatal
diabetes, but a role of this gene in T2D has not been yet
reported30.
The lead common variant of the fourth novel locus at
chromosome 12q24.31 (rs3794205, OR = 1.07 [1.04–1.10], p=
4.1 × 10−8) lies within an intron of the CAMKK2 gene, previously
implicated in cytokine-induced beta-cell death31. However, other
variants within the corresponding credible set could also be
causal, such as a missense variant within the P2RX7, a gene
previously associated with glucose homeostasis in humans and
mice32, or another variant (rs11065504, r2 with lead variant =
0.81) found to be associated with the regulation of the P2RX4
gene in tibial artery and in whole blood, according to GTEx
(Supplementary Data 9).
The ﬁfth novel locus driven by common variants is
located within 17q21.32 (rs12453394, OR = 1.07 [1.05–1.10],
p= 3.23 × 10−8). It includes three missense variants located
within the CALCOCO2, SNF8, and GIP genes. GIP encodes for
glucose-dependent insulinotropic peptide, a hormonal mediator
of enteral regulation of insulin secretion33. Variants in the GIP
receptor (GIPR) have been previously associated with insulin
response to oral glucose challenge and beta-cell function34,
proposing GIP as a plausible candidate effector gene of this
locus35.
A new T2D signal driven by a low-frequency variant. Fur-
thermore, we selected all low-frequency (0.01 ≤MAF< 0.05)
variants with p ≤ 1 × 10−4 in the 70KforT2D meta-analysis that
Table 1 Novel T2D-associated loci
OR (95% CI) P-value
Novel Locus Chr rsID––Risk Allele Stage1 Discovery Meta-
analysis
Stage2 Replication
Meta-analysis
Stage1 + Stage2
Combined Meta-
analysis
MAF
LYPLAL1/ZC3H11B
(1q41)
1 rs2820443-T 1.08 (1.04–1.13)
2.94 × 10−4 a
1.06 (1.03–1.09)
2.10 × 10−5 b
1.07 (1.04–1.09)
2.56 × 10−8 c
0.28
EHMT2
(6p21.33–p21.32)
6 rs115884658-A 1.34 (1.18–1.53)
1.00 × 10−5 a
1.17 (1.09–1.26)
2.90 × 10−6 c, d
1.21 (1.14–1.29)
3.00 × 10−10 c
0.02
ABO
(9q34.2)
9 rs505922-C 1.07 (1.03–1.11)
6.93 × 10−4 a
1.06 (1.03–1.09)
1.90 × 10−5 b
1.06 (1.04–1.09)
4.94 × 10−8 c
0.34
NEUROG3
(10q22.1)
10 rs2642587-G 1.12 (1.08–1.16)
8.45 × 10−9 e
- - 0.22
CAMKK2
(12q24.31)
12 rs3794205-G 1.09 (1.05–1.14)
4.18 × 10−5 a
1.06 (1.03–1.09)
1.60 × 10−4 b
1.07 (1.04–1.10)
4.11 × 10−8 c
0.32
CALCOCO2/ATP5G1/
UBE2Z/SNF8/GIP
(17q21.32)
17 rs12453394-A 1.08 (1.04–1.12)
7.86 × 10−5 a
1.07 (1.03–1.11)
9.60 × 10−5 b
1.07 (1.05–1.10)
3.23 × 10−8 c
0.47
AGTR2
(Xq23)
X rs146662075-T 3.09 (2.06–4.60)
3.24 × 10−8 f
1.57 (1.19–2.07)
1.42 × 10−3 g
1.95 (1.56–2.45)
7.85 × 10−9
0.008
Chr chromosome, OR odds ratio, MAF minor allele frequency
aImputed based public GWAS discovery meta-analysis (NuGENE + GERA cohort, 7,522 cases and 50,446 controls)
bTransancestry DIAGRAM Consortium (26,488 cases and 83,964 controls)cMeta P-value estimated using a weighted Z-score method due to unavailable SE information from Stage 2 replication
cohortsdT2D Diabetes Genetic Portal (Exome-Chip + Exome Sequencing, 35,789 cases and 56,738 controls)eFull imputed based public GWAS meta-analysis (NuGENE + GERA cohort + GENEVA +
FUSION +WTCCC, 12,931 cases and 57,196 controls)
f70KforT2D Men Cohort (GERA cohort + GENEVA + FUSION, 5,277 cases and 15,702 controls older than 55 years)
gReplication Men Cohort SIGMA UK10K imputation + InterAct + Danish Cohort (case control and follow-up) + Partners Biobank + UK Biobank (18,370 cases and 88,283 controls older than 55 years and
OGTT> 7.8 mmol l−1, when available)
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were annotated as altering protein sequences, according to VEP.
This resulted in 15 coding variants that were meta-analyzed with
exome array and whole-exome sequencing data from a total of
~97,000 individuals6 after excluding the overlapping cohorts
between the different data sets. This analysis highlighted a novel
genome-wide association driven by a low-frequency missense
variant (Ser58Phe) within the EHMT2 gene at chromosome
6p21.33 (rs115884658, OR = 1.21 [1.14–1.29], p = 3.00 × 10−10;
Fig. 2, Supplementary Figures 6 and 7). EHMT2 is involved in the
mediation of FOXO1 translocation induced by insulin36. Since
this variant is less than 1Mb away from HLA-DQA1, a locus
reported to be associated with T2D37, we performed a series of
reciprocal conditional analyses and excluded the possibility that
our analysis was capturing previously reported T2D8, 37 or
T1D38–40 signals (Supplementary Data 11). Beyond this missense
EHMT2 variant, other low-frequency variants within the corre-
sponding credible set may also be causal. For example,
rs115333512 (r2 with lead variant = 0.28) is associated with the
expression of CLIC1 in several tissues according to GTEx (mul-
titissue meta-analysis p= 8.9 × 10−16, Supplementary Data 9). In
addition, this same variant is associated with the expression of the
ﬁrst and second exon of the CLIC1 mRNA in pancreatic islet
donors (p(exon 1) = 1.4 × 10−19, p(exon 2) = 1.9 × 10−13, Supple-
mentary Data 10). Interestingly, CLIC1 has been reported as a
direct target of metformin by mediating the antiproliferative
effect of this drug in human glioblastoma41. All these ﬁndings
support CLIC1, as an additional possible effector transcript, likely
driven by rs115333512.
A novel rare X chromosome variant associated with T2D.
Similar to other complex diseases, the majority of published large-
scale T2D GWAS studies have omitted the analysis of the X
chromosome, with the notable exception of the identiﬁcation of a
T2D-associated region near the DUSP9 gene in 201042. To ﬁll this
gap, we tested the X chromosome genetic variation for association
with T2D. To account for heterogeneity of the effects and for the
differences in imputation performance between males and
females, the association was stratiﬁed by sex and tested separately,
and then meta-analyzed. This analysis was able to replicate the
DUSP9 locus, not only through the known rs5945326 variant
(OR = 1.15, p = 0.049), but also through a three-nucleotide dele-
tion located within a region with several promoter marks in liver
(rs61503151 [GCCA/G], OR = 1.25, p = 3.5 × 10−4), and in high
LD with the ﬁrst reported variant (r2 = 0.62). Conditional analyses
showed that the originally reported variant was no longer sig-
niﬁcant (OR = 1.01, p = 0.94) when conditioning on the newly
identiﬁed variant, rs61503151. On the other hand, when con-
ditioning on the previously reported variant, rs5945326, the effect
of the newly identiﬁed indel remained signiﬁcant and with a
larger effect size (OR = 1.33, p = 0.003), placing this deletion, as a
more likely candidate causal variant for this locus (Supplementary
Data 14).
In addition, we identiﬁed a novel genome-wide signiﬁcant
signal in males at the Xq23 locus driven by a rare variant
(rs146662075, MAF = 0.008, OR = 2.94 [2.00–4.31], p = 3.5 × 10−8;
Fig. 3a). Two other variants in LD with the top variant,
rs139246371 (chrX:115329804, OR = 1.65, p = 3.5 × 10−5, r2 =
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Fig. 2Manhattan and quantile–quantile plot (QQ-plot) of the discovery and replication genome-wide meta-analysis. The upper corner represents the QQ-
plot. Expected −log10 p-values under the null hypothesis are represented in the x axis, while observed −log10 p-values are represented in the y axis.
Observed p-values were obtained according to the suitable replication dataset used (as shown in Fig. 1) and were depicted using different colors. HapMap
variants were meta-analyzed using the trans-ethnic summary statistics from the DIAGRAM study and our meta-analysis based on the Genetic
Epidemiology Research on Aging (GERA) cohort and the northwestern NuGENE project, and that resulted in novel associations depicted in magenta. The
rest of non-HapMap variants meta-analyzed using the full 70KforT2D cohort are represented in gray, and the fraction of novel GWAS-signiﬁcant variants
is highlighted in light blue. Coding low-frequency variants meta-analyzed using the 70KforT2D and the T2D Portal data that resulted in novel GWAS-
signiﬁcant associations are depicted in green. The shaded area of the QQ-plot indicates the 95% conﬁdence interval under the null and a density function
of the distribution of the p-values was plotted using a dashed line. The λ is a measure of the genomic inﬂation and corresponds to the observed median χ2
test statistic divided by the median expected χ2 test statistic under the null hypothesis. The Manhattan plot, representing the −log10 p-values, was colored
as explained in the QQ-plot. All known GWAS-signiﬁcant associated variants within known T2D genes are also depicted in red. X chromosome results for
females (F), males (M), and all individuals (A) are also included
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0.37 with the top variant) and rs6603744 (chrX:115823966,
OR = 1.28, p = 1.7 × 10−4, r2 = 0.1 with the top variant), comprised
the 99% credible set and supported the association. We
tested in detail the accuracy of the imputation for the
rs146662075 variant by comparing the imputed results from the
same individuals genotyped by two different platforms (Methods)
and found that the imputation was highly accurate in
males only when using UK10K, but not in females, nor
when using 1000G (R2[UK10K,males] = 0.94, R2[UK10K,females] = 0.66,
R2[1000G,males] = 0.62, and R2[1000G,females] = 0.43; Supplementary
Fig. 8). Whether this association is speciﬁc to men, or whether it
also affects female carriers, remains to be clariﬁed with datasets
that allow accurate imputation on females, or with direct
genotyping or sequencing.
To further validate and replicate this association, we next
analyzed four independent data sets (SIGMA6, INTERACT43,
Partners Biobank44, and UK Biobank45), by performing imputa-
tion with the UK10K reference panel. In addition, a ﬁfth cohort
was genotyped de novo for the rs146662075 variant in several
Danish sample sets. The initial meta-analysis, including the
ﬁve replication data sets did not reach genome-wide signiﬁcance
(OR = 1.57, p = 1.2 × 10−5; Supplementary Fig. 9A), and revealed a
strong degree of heterogeneity (heterogeneity phet = 0.004), which
appeared to be driven by the replication cohorts.
As a complementary replication analysis, within one of the
case-control studies, there was a nested prospective cohort study,
the Inter99, which consisted of 1,652 nondiabetic male subjects
genotyped for rs146662075, of which 158 developed T2D after 11
years of follow-up. Analysis of incident diabetes in this cohort
conﬁrmed the association with the same allele, as previously seen
in the case-control studies, with carriers of the rare T allele having
increased risk of developing incident diabetes, compared to the C
carriers (Cox-proportional hazards ratio (HR) = 3.17 [1.3–7.7], p
= 0.011, Fig. 3b). Nearly 30% of carriers of the T risk allele
developed incident T2D during 11 years of follow-up, compared
to only 10% of noncarriers.
To understand the strong degree of heterogeneity observed
after adding the replication datasets, we compared the clinical and
demographic characteristics of the discovery and replication
cohorts, and found that the majority of the replication datasets
contained control subjects that were signiﬁcantly younger than 55
years, the average age at the onset of T2D reported in this study
and in Caucasian populations46. This was particularly clear for
the Danish cohort (age controls [95%CI] = 46.9 [46.6–47.2] vs.
age cases [95%CI] = 60.7 [60.4–61.0]) and for INTERACT (age
controls [95%CI] = 51.7 [51.4–52.1] vs. age cases [95%CI] = 54.8
[54.6–55.1]; Supplementary Fig. 10). Given the supporting results
with the Inter99 prospective cohort, we performed an additional
analysis using a stricter deﬁnition of controls, to minimize the
presence of prediabetics or individuals that may further develop
diabetes after reaching the average age at the onset. For this, we
applied two additional exclusion criteria: (i) subjects younger
than 55 years and (ii), when possible, excluding individuals with
measured 2- h plasma glucose values during oral glucose
tolerance test (OGTT) above 7.8 mmol l−1, a threshold employed
to identify impaired glucose tolerance (prediabetes)47, or controls
with family history of T2D, both being strong risk factors for
developing T2D. While the application of the ﬁrst ﬁlter alone did
not yield genome-wide signiﬁcant results (Supplementary Fig. 9B),
upon excluding individuals with prediabetes or a family history of
T2D, the replication results were signiﬁcant and consistent with
the initial discovery results (OR = 1.57 [1.19–2.07], p = 0.0014).
The combined analysis of the discovery and replication cohorts
resulted in genome-wide signiﬁcance, conﬁrming the association
of rs146662075 with T2D (OR = 1.95 [1.56–2.45], p = 7.8 × 10−9,
Fig. 3c).
Allele-speciﬁc enhancer activity of the rs146662075 variant. We
next explored the possible molecular mechanism behind this
association, by using different genomic resources and experi-
mental approaches. The credible set of this region contained three
variants, with the leading SNP alone (rs146662075), showing 78%
posterior probability of being causal (Supplementary Fig. 7,
Supplementary Data 5), as well as the highest CADD (scaled C-
score = 15.68; Supplementary Data 8), and LINSIGHT score
(Supplementary Data 9). rs146662075 lies within a chromosomal
region enriched in regulatory (DNase I) and active enhancer
(H3K27ac) marks, between the AGTR2 (at 103 kb) and the
SLC6A14 (at 150 kb) genes. The closest gene AGTR2, which
encodes for the angiotensin II receptor type 2, has been pre-
viously associated with insulin secretion and resistance48–50.
From the analysis of available epigenomic data sets51, we found
no evidences of H3K27ac or other enhancer regulatory marks in
human pancreatic islets; whereas a signiﬁcant association was
observed between the presence of H3K27ac enhancer marks and
the expression of AGTR2 across multiple tissues (Fisher test p =
4.45 × 10−3), showing the highest signal of both H3K27ac and
AGTR2 RNA-seq expression, but not with other genes from the
same topologically associated domain (TAD), in fetal muscle
(Fig. 4a; Supplementary Figure 11).
We next studied whether the region encompassing the
rs146662075 variant could act as a transcriptional enhancer and
whether its activity was allele-speciﬁc. For this, we linked the
DNA region with either the T (risk) or the C (non-risk) allele, to a
minimal promoter and performed luciferase assays in a mouse
myoblast cell line. The luciferase analysis showed an average 4.4-
fold increased activity for the disease-associated T allele,
compared to the expression measured with the common C allele,
suggesting an activating function of the T allele, or a repressive
function of the C allele (Fig. 4b). Consistent with these ﬁndings,
electrophoretic mobility shift assays using nuclear protein extracts
from mouse myoblast cell lines, differentiated myotubes, and
human fetal muscle cell line, revealed sequence-speciﬁc binding
activity of the C allele, but not the rare T allele (Fig. 4c). Overall,
these data indicate that the risk T allele prevents the binding of a
nuclear protein that is associated with decreased activity of an
AGTR2-linked enhancer.
Discussion
Through harmonizing and reanalyzing publicly available T2D
GWAS data, and performing genotype imputation with two
whole-genome sequence-based reference panels, we are able to
perform deeper exploration of the genetic architecture of T2D.
This strategy allowed us to impute and test for association with
T2D more than 15 million of high-quality imputed variants,
including low-frequency, rare, and small insertions and deletions,
across chromosomes 1–22 and X.
The reanalysis of these data conﬁrmed a large fraction of
already-known T2D loci, and identiﬁed novel potential causal
variants by ﬁne mapping and functionally annotating each locus.
This reanalysis also allowed us to identify seven novel asso-
ciations, ﬁve driven by common variants in or near LYPLAL1,
NEUROG3, CAMKK2, ABO, and GIP; a low-frequency variant in
EHMT2, and a rare variant in the X chromosome. This rare
variant identiﬁed in Xq23 chromosome was located near
the AGTR2 gene, and showed nearly twofold increased risk for
T2D in males, which represents, to our knowledge, the
largest effect size identiﬁed so far in Europeans, and a magnitude
similar to other variants with large effects identiﬁed in other
populations52, 53.
Our study complemented other efforts that also aim at unra-
veling the genetics behind T2D through the generation of new
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genetic data6, 54. For example, we provided for the ﬁrst time a
comprehensive coverage of structural variants, which point to
previously unobserved candidate causal variants in known and
novel loci, as well as a comprehensive coverage of the X chro-
mosome through sequence-based imputation.
This study also highlights the importance of a strict classiﬁ-
cation of both cases and controls, in order to identify rare variants
associated with disease. Our initial discovery of the Xq23 locus
was only replicated when the control group was restricted to
T2D-free individuals who were older than 55 years (average age
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at the onset of T2D), had normal glucose tolerance, and no family
history of T2D. This is in line with previous results obtained for a
T2D population-speciﬁc variant found in Inuit within the
TBC1D4 gene, which was only signiﬁcant when using OGTT as
criteria for classifying cases and controls, but not when using
HbA1c52. Our observation that 30% of the rs146662075 risk allele
carriers developed T2D over 11 years of follow-up, compared to
10% of noncarriers, further supports the association of this var-
iant and suggests that an early identiﬁcation of these subjects
through genotyping may be useful to tailor pharmacological or
lifestyle intervention to prevent or delay the onset of T2D.
Using binding and gene-reporter analyses, we demonstrated a
functional role of this variant and proposed a possible mechanism
behind the pathophysiology of T2D in T risk allele carriers, in
which this rare variant could favor a gain of function of AGTR2,
previously associated with insulin resistance48. AGTR2 appears,
therefore, as a potential therapeutic target for this disease, which
would be in line with previous studies showing that the blockade
of the renin–angiotensin system in mice55 and in humans56
prevents the onset of T2D, and restores normoglycemia57, 58.
Overall, beyond our signiﬁcant contribution toward expanding
the number of genetic associations with T2D, our study also
highlights the potential of the reanalysis of public data, as a
complement to large studies that use newly generated data. This
study informs the open debate in favor of data sharing and
democratization initiatives4, 59, for investigating the genetics and
pathophysiology of complex diseases, which may lead to new
preventive and therapeutic applications.
Methods
Quality ﬁltering for imputed variants. In order to assess genotype imputation
quality and to determine an accurate post-imputation quality ﬁlter, we made use of
the Wellcome Trust Case Control Consortium (WTCCC)40 data available through
the European Genotype Archive (EGA, https://www.ebi.ac.uk/ega/studies/
EGAS00000000028). The genotyping data and the subjects included in the fol-
lowing tests were ﬁltered according to the guidelines provided by the WTCCC,
whose criteria of exclusion are in line with standard quality ﬁlters for GWAS60. We
used the 1958 British Birth cohort (~3,000 samples, 58C) that was genotyped by
Affymetrix v6.0 and Illumina 1.2M chips. After applying the quality-ﬁltering cri-
teria, 2,706 and 2,699 subjects from the Affymetrix and Illumina data, respectively,
were available for the 58C samples, leaving an intersection of 2,509 individuals
genotyped by both platforms. After variant quality ﬁltering and excluding all the
variants with minor allele frequency (MAF) below 0.01, 717,556, and 892,516
variants remained for 58C Affymetrix and Illumina platforms, respectively.
We used a two-step genotype imputation approach based on prephasing the
study genotypes into full haplotypes with SHAPEIT261 to ameliorate the
computational burden required for genotype imputation through IMPUTE262. We
used the GTOOL software (http://www.well.ox.ac.uk/~cfreeman/software/gwas/
gtool.html, version 0.7.5) to homogenize strand annotation by merging the
imputed results obtained from each set of genotyped data. To ensure that there
were no strand orientation issues, we excluded all C/G and A/T SNPs. To perform
genotype imputation, we used two sequence-based reference panels: the 1000G
Phase1 (June 2014) release7 and the UK10K2.
We evaluated genotype imputation for each reference panel considering 2,509
58C individuals that were genotyped by both independent genotyping platforms.
Four scenarios were considered: (a) fraction of variants originally genotyped (GT)
by both Illumina (IL) and Affymetrix (Affy) platforms (both GT), (b) variants
genotyped by Affy, but not present in IL array (Affy GT), (c) variants genotyped by
IL, but not present in the Affy array (IL GT), and (d) variants not typed in IL nor in
the Affy arrays, and therefore, imputed from IL and Affy data sets (d). This last
scenario comprised the largest fraction of variants.
As the individuals typed (and imputed) using Affy and IL SNPs as backbones
were the same, we expected no statistical differences when comparing the allele and
genotype frequencies with any of the variants. The quality of the imputed variants
was evaluated using the allelic dosage R2 correlation coefﬁcient, between the
genotype dosages estimated when imputing using Affy or IL as the backbone. The
Affy GT and IL GT SNPs were used to evaluate the correspondence between the
allelic dosage R2 scores and the IMPUTE2 info scores for the imputed genotypes.
The linear model, between the allelic dosage R2 and the IMPUTE2-info, was used
to set an info score threshold of 0.7, which corresponds to an allelic dosage R2 of
0.5. The correlation between R2 and info score was uniform across all reference
panels and platforms.
The 70KforT2D resource. We collected genetic individual-level data for T2D
case/control studies from ﬁve independent datasets, Gene Environment-
Association Studies initiative [GENEVA], Wellcome Trust Case Control Con-
sortium [WTCCC], Finland–United States Investigation of NIDDM Genet-
ics [FUSION], Resource for Genetic Epidemiology Research on Aging [GERA],
and the Northwestern NUgene project [NuGENE] publicly available in the dbGaP
(http://www.ncbi.nlm.nih.gov/gap) and EGA (https://www.ebi.ac.uk/ega/home)
public repositories, comprising a total of 13,201 cases and 59,656 controls (for the
description of each cohort, see Supplementary Note 1 and Supplementary Data 1).
Each dataset was independently harmonized and quality controlled with a
three-step protocol, including two stages of SNP removal and an intermediate stage
of sample exclusion. The exclusion criteria for variants were (i) missing call rate
≥ 0.05, (ii) signiﬁcant deviation from Hardy–Weinberg equilibrium (HWE) p ≤ 1 ×
10−6 for controls and p≤ 1 × 10−20 for the entire cohort, (iii) signiﬁcant differences
in the proportion of missingness between cases and controls p ≤ 1 × 10−6, and (iv)
MAF < 0.01 (for the GERA cohort, we considered a MAF of 0.001). The exclusion
criteria for samples were i) gender discordance between the reported and
genetically predicted sex, ii) subject relatedness (pairs with π ≥ 0.125 from which
we removed the individual with the highest proportion of missingness), iii) missing
call rates per sample ≥ 0.02, and iv) population structure showing more than four
standard deviations within the distribution of the study population according to
the ﬁrst four principal components.
We performed genotype imputation independently for each cohort by
prephasing the genotypes to whole haplotypes with SHAPEIT2 and then, we
performed genotype imputation with IMPUTE2. We tested for association with
additive logistic regression using SNPTEST, seven derived principal components
sex, age, and body-mass index (BMI), except for WTCCC, for which age and BMI
were not available (Supplementary Data 1). To maximize power and accuracy, we
combined the association results from 1000G Phase1 integrated haplotypes (June,
2014)7 and UK10K (http://www.uk10k.org/) reference panels by choosing for each
variant, the reference panel that provided the best IMPUTE2 info score. For
1000G-based genotype imputation in chromosome X (chrX), we used the “v3.
macGT1” release (August, 2012). For chrX, we restricted the analysis to non-
pseudoautosomal (non-PAR) regions and stratiﬁed the association analysis by sex
to account for hemizygosity for males, while for females, we followed an autosomal
model. Also, we did not apply HWE ﬁltering in the X chromosome variants.
Finally, for the GERA cohort due to the large computational burden that comprises
the whole genotype imputation process in such a large sample size, we randomly
split this cohort into two homogeneous subsets of ~30,000 individuals each, in
order to minimize the memory requirements.
We included variants with IMPUTE2 info score ≥ 0.7, MAF ≥ 0.001, and for
autosomal variants, HWE controls p> 1 × 10−6. Further details about genotype
imputation and covariate information used in association testing are summarized
in Supplementary Data 1.
70KforT2D and inclusion of previous summary statistics data. We meta-
analyzed the different sets from the 70KforT2D data set with METAL63, using the
inverse variance-weighted ﬁxed effect model. We included variants with I2 het-
erogeneity < 75. This ﬁlter was not applied to the ﬁnal X chromosome data set,
after meta-analyzing the results from males and females separately (which were
already ﬁltered by I2< 75).
For the meta-analysis with the DIAGRAM trans-ethnic study8, we excluded
from the whole 70KforT2D datasets those cohorts that overlapped with the
DIAGRAM data. Therefore, we meta-analyzed the GERA and NuGENE cohorts
(7,522 cases and 50,446 controls) from the 70KforT2D analysis with the trans-
ethnic summary statistics results. As standard errors were not provided for the
Fig. 4 Functional characterization of rs146662075 association signal. a Signal plot for X chromosome region surrounding rs146662075. Each point
represents a variant, with its p-value (on a −log10 scale, y axis) derived from the meta-analysis results from association testing in males. The x axis
represents the genomic position (hg19). Below, representation of H3K27ac and RNA-seq in a subset of cell types is shown. The association between RNA-
seq signals and H3K27ac marks suggests that AGTR2 is the most likely regulated gene by the enhancer that harbors rs146662075. b The presence of the
common allelic variant rs146662075-C reduces enhancer activity in luciferase assays performed in a mouse myoblast cell line. c Electrophoretic mobility
shift assay in C2C12 myoblast cell lines, C2C12-differentiated myotubes, and human fetal myoblasts showed allele-speciﬁc binding of a ubiquitous nuclear
complex. The arrows indicate the allele-speciﬁc binding event. Competition was carried out using 50- and 100-fold excess of the corresponding unlabeled
probe
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DIAGRAM trans-ethnic meta-analysis, we performed a sample size based meta-
analysis, which converts the direction of the effect and the p-value into a Z-score.
In addition, we also performed an inverse variance-weighted ﬁxed effect meta-
analysis to estimate the ﬁnal effect sizes. This approach required the estimation of
the beta and standard errors from the summary statistics (p-value and odds ratio).
For the meta-analysis of coding low-frequency variants with the
Type 2 Diabetes Knowledge Portal (T2D Portal)6, we included from the
70KforT2D data set the NuGENE and GERA cohorts (7,522 cases and 50,446
controls), to avoid overlapping samples. Like in the previous scenario, standard
errors were not provided for the T2D Portal data and we used a sample size based
meta-analysis with METAL. However, to estimate the effect sizes, we also
calculated the standard errors from the p-values and odds ratios, and we performed
an inverse variance-weighted ﬁxed effect meta-analysis.
See further details about the cohorts in Supplementary Note 1.
Pathway and enrichment analysis. Summary statistics that resulted from the
70KforT2D meta-analysis were analyzed by Data-driven Expression-Prioritized
Integration for Complex Traits (DEPICT)9 to prioritize likely causal genes, to
highlight enriched pathways, and to identify the most relevant tissues/cell types;
DEPICT relies on publicly available gene sets (including molecular pathways) and
leverages gene expression data from 77,840 gene expression arrays, to perform gene
prioritization and gene-set enrichment based on predicted gene function and the
so-called reconstituted gene sets. A reconstituted gene set contains a membership
probability for each gene and conversely, each gene is functionally characterized by
its membership probabilities across 14,461 reconstituted gene sets. As an input to
DEPICT, we used all summary statistics from autosomal variants with p< 1 × 10−5
in the 70KforT2D meta-analysis. We used an updated version of DEPICT, which
handled 1000G Phase1-integrated haplotypes (June 2014, www.broadinstitute.org/
depict). DEPICT was run using 3,412 associated SNPs (p < 1 × 10−5), from which
we identiﬁed independent SNPs using PLINK and the following parameters:
--clump-p1 5e-8, --clump-p2 1e-5, --clump-r2 0.6, and --clump-kb 250. We used
LD r2> 0.5 distance to deﬁne locus limits yielding 70 autosomal loci comprising
119 genes (note that this is not the same locus deﬁnition that we used elsewhere in
the text). We ran DEPICT with default settings, i.e., using 500 permutations to
adjust for bias and 50 replications to estimate false discovery rate (FDR). We used
normalized expression data from 77,840 Affymetrix microarrays to reconstitute
gene sets9. The resulting 14,461 reconstituted gene sets were tested for enrichment
analysis. A total of 209 tissue or cell types expression data assembled from 37,427
Affymetrix U133 Plus 2.0 Array samples were used for enrichment in tissue/cell-
type expression. DEPICT identiﬁed 103 reconstituted gene sets signiﬁcantly enri-
ched (FDR< 5%) for genes found among the 70 loci associated to T2D. We did not
consider reconstituted sets in which genes of the original gene set were not
nominally enriched (Wilcoxon rank-sum test), as these are expected to be enriched
in the reconstituted gene set by design. The lack of enrichment makes the inter-
pretation of the reconstituted gene set challenging because the label of the
reconstituted gene set will not be accurate. Hence, the following reconstituted gene
sets were removed from the results (Wilcoxon rank sum and P-values in par-
entheses): MP:0004247 gene set (p = 0.73), GO:0070491 gene set (p = 0.14),
MP:0004086 gene set (p = 0.17), MP:0005491 gene set (p = 0.54), GO:0005159 gene
set (p = 0.04), MP:0005666 gene set (p = 0.05), ENSG00000128641 gene set (p =
0.02), MP:0006344 gene set (p = 0.42), MP:0004188 gene set (p = 0.22),
MP:0002189 gene set (p = 0.02), MP:0000003 gene set (p = 0.08),
ENSG00000116604 gene set (p = 0.13), GO:0005158 gene set (p = 0.07), and
MP:0001715 gene set (p = 0.01). After applying the ﬁlters described above, there
were 89 signiﬁcantly enriched reconstituted gene sets. We used the afﬁnity pro-
pagation tool to cluster related reconstituted gene sets (network diagram script
available from https://github.com/perslab/DEPICT).
We also used the VSE R package to compute the enrichment or depletion of
genetic variants comprised in the 57 credible sets listed in Supplementary Data 5
across regulatory genomic annotations, as described in64. Each GWAS lead variant
from the ﬁnal meta-analysis was considered as a tag SNP and variants from the
corresponding 99% credible set (Supplementary Data 5) in LD with the tag SNP
(R2 ≥ 0.4), as a cluster or associated variant set (AVS). In order to account for the
size and structure of the AVS, a null distribution was built based on random
permutations of the AVS. Each permuted variant set was matched to the original
AVS, cluster by cluster using HapMap data by size and structure. This Matched
Random Variant Set (MRVS) was calculated using 500 permutations. Signiﬁcant
enrichments or depletions were considered when the Bonferroni-adjusted p-value
was < 0.01. Human islet regulatory elements (C1–C5) were obtained from10.
Deﬁnition of 99% credible sets of GWAS-signiﬁcant loci. For each genome-
wide signiﬁcant region locus, we identiﬁed the fraction of variants that have, in
aggregate, 99% probability of containing the causal T2D-associated variant. By
using our 70KforT2D meta-analysis based on imputed data (NuGENE, GERA,
FUSION, GENEVA, and WTCCC data sets, comprising 12,231 cases and 57,196
controls), we deﬁned the 99% credible set of variants for each locus with a Bayesian
reﬁnement approach11 (we considered variants with an R2> 0.1 with their
respective leading SNP).
Credible sets of variants are analogous to conﬁdence intervals as we assume that
the credible set for each associated region contains, with 99% probability, the true
causal SNP if this has been genotyped or imputed. The credible set construction
provides, for each variant placed within a certain associated locus, a posterior
probability of being the causal one11. We estimated the approximate Bayes’ factor
(ABF) for each variant as
ABF ¼ ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ1 rp e rz2=2ð Þ;
where
r ¼ 0:04
SE2 þ 0:04ð Þ ;
z ¼ β
SE
:
The β and the SE are the estimated effect size and the corresponding standard
error resulting from testing for association under a logistic regression model. The
posterior probability for each variant was obtained as
Posterior Probabilityi ¼
ABFi
T
;
where ABFi corresponds to the approximate Bayes’ factor for the marker i and T
represents the sum of all the ABF values from the candidate variants enclosed in
the interval being evaluated. This calculation assumes that the prior of the β
corresponds to a Gaussian with mean 0 and variance 0.04, which is also the same
prior commonly employed by SNPTEST, the program being used for calculating
single-variant associations.
Finally, we ranked variants according to the ABF (in decreasing order) and from
this ordered list, we calculated the cumulative posterior probability. We included
variants in the 99% credible set of each region until the SNP that pushed the
cumulative posterior probability of association over 0.99.
The 99% credible sets of variants for each of the 57 GWAS-signiﬁcant regions
are summarized in Supplementary Data 5.
Characterization of indels. We examined whether indels from the 99% credible
sets were present or absent in the 1000G Phase1 or UK10K reference panels, and
also checked whether they were present or not in the 1000G Phase3 reference
panel. All the information has been summarized in Supplementary Data 6. We also
visually inspected the aligned BAM ﬁles of the most relevant indels from both
projects to discard that they could be alignment artifacts.
Functional annotation of the 99% credible set variants. To determine the effect
of 99% credible set variants on genes, transcripts, and protein sequence, we used
the variant effect predictor (VEP, GRCh37.p13 assembly)13. The VEP application
determines the effect of variants (SNPs, insertions, deletions, CNVs, or structural
variants) on genes, transcripts, proteins, and regulatory regions. We used as input
the coordinates of variants within 99% credible sets and the corresponding alleles,
to ﬁnd out the affected genes and RefSeq transcripts and the consequence on the
protein sequence by using the GRCh37.p13 assembly. We also manually checked
all these annotations with the Exome Aggregation Consortium data set (ExAC,
http://exac.broadinstitute.org) and the most updated VEP server based on the
GRCh38.p7 assembly. All these annotations are provided in Supplementary Data 7.
We used combined annotation-dependent depletion (CADD) scoring function
to prioritize functional, deleterious, and disease causal variants. We obtained
the scaled C-score (PHRED-like scaled C-score ranking each variant with respect to
all possible substitutions of the human genome) metric for each 99% credible set
variant, as it highly ranks causal variants within individual genome sequences14
(Supplementary Data 8). We also used the LINSIGHT score to prioritize functional
variants, which measures the probability of negative selection on noncoding sites
by combining a generalized linear model for functional genomic data with a
probabilistic model of molecular evolution15. For each credible set variant, we
retrieved the precomputed LINSIGHT score at that particular nucleotide site, as
well as the mean LINSIGHT precomputed score for a region of 20 bp centered on
each credible set variant, respectively (https://github.com/CshlSiepelLab/
LINSIGHT). These metrics are summarized in Supplementary Data 9.
In order to prioritize functional regulatory variants, we used the V6 release from
the GTEx data that provides gene-level expression quantiﬁcations and eQTL results
based on the annotation with GENCODE v19. This release included 450 genotyped
donors, 8,555 RNA-seq samples across 51 tissues, and two cell lines, which led to
the identiﬁcation of eQTLs across 44 tissues16. Moreover, RNA-seq data from
human pancreatic islets from 89 deceased donors cataloged as eQTLs and exon use
(sQTL) were also integrated with the GWAS data to prioritize candidate regulatory
variants17 but in pancreatic islets, which is a target tissue for T2D. Both analyses
are summarized in Supplementary Data 10 and Supplementary Data 11,
respectively.
Conditional analysis. To conﬁrm the independence between novel loci and pre-
viously known T2D signals, we performed reciprocal conditional analyses (Sup-
plementary Data 5, Supplementary Data 12, Supplementary Data 13, and
Supplementary Data 14). We included the conditioning SNP as a covariate in the
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logistic regression model, assuming that every residual signal that arises corre-
sponds to a secondary signal independent from this conditioning SNP. We applied
this method to the EHMT2 locus (less than 1Mb away from the HLA where T2D
and T1D signals have been identiﬁed), to conﬁrm that this association was inde-
pendent of previously reported T2D signals and also to discard that this association
is also driven by possible contamination of T1D diagnosed as T2D cases. We
conditioned on the top variant identiﬁed in this study and the top variant from the
99% credible set analysis, but also on the top variants previously described for T2D
and T1D8, 38–40. For this purpose, we used the full 70KforT2D resource (NuGENE,
GERA, FUSION, GENEVA, and WTCCC cohorts imputed with 1000G and
UK10K reference panels). Finally, all the results were meta-analyzed as explained in
previous sections. These analyses are provided in Supplementary Data 13. This
approach was also applied to conﬁrm that the novel CAMKK2 signal at rs3794205
is independent of known T2D signals at the HNF1A locus (rs1169288, rs1800574,
and chr12:121440833:D)54, which is summarized in Supplementary Data 12.
Moreover, this approach conﬁrmed known secondary signals in the 9p21 locus65
which allowed us to build 99% credible sets based on the results from the condi-
tional analyses (included in Supplementary Data 5), and allowed us to identify the
most likely causal variant for the DUSP9 locus (Supplementary Data 14).
Replication of the rare variant association at Xq23. To replicate the association
of the rs146662075 variant, we performed genotype imputation with the UK10K
reference panel in four independent data sets: the InterAct case-cohort study43, the
Slim Initiative in Genomic Medicine for the Americas (SIGMA) consortium
GWAS data set6, the Partners HealthCare Biobank (Partners Biobank) data set44,
and the UK Biobank cohort45. Phasing was performed with SHAPEIT2 and the
IMPUTE2 software was used for genotype imputation.
The current UK Biobank data release did not contain imputed data for the X
chromosome, for which phasing and imputation had to be analyzed in-house. The
data release used comprises X chromosome QCed genotypes of 488,377
participants, which were assayed using two arrays sharing 95% of marker content
(Applied BiosystemsTM UK BiLEVE AxiomTM Array and the Applied
BiosystemsTM UK Biobank AxiomTM Array). We included samples and markers
that were used as input for phasing by UK Biobank investigators. At the sample
level, we also excluded women, individuals with missing call rate > 5% or showing
gender discordance between the reported and the genetically predicted sex. At the
variant level, we excluded markers with MAF< 0.1% and with missing call rate
> 5%. The ﬁnal set of 16,463 X chromosome markers and 222,725 male individuals
was split into six subsets due to the huge computational burden that would require
phasing into whole haplotypes the entire data set. We also excluded indels, variants
with MAF< 1%, and variants showing deviation of Hardy–Weinberg equilibrium
with p < 1 × 10−20 before the imputation step. In addition, from those pairs of
relatives reported to be third degree or higher according to UK Biobank, we
excluded from each pair the individual with the lowest call rate. We then tested the
rs146662075 variant for association with type 2 diabetes using SNPTEST v2.5.1 and
the threshold method. To avoid contamination from other types of diabetes
mellitus, we excluded from the entire sample data set, individuals with ICD10
codes falling in any of these categories: E10 (insulin-dependent diabetes mellitus),
E13 (other speciﬁed diabetes mellitus), and E14 (unspeciﬁed diabetes mellitus).
Then, we designated as T2D cases those individuals with E11 (non-insulin-
dependent diabetes mellitus) ICD10 codes, and the rest as controls. Moreover, we
only kept as control subjects those individuals without reported family history of
diabetes mellitus and older than 55 years, which is the average age at the onset of
T2D.
We also genotyped de novo the rs146662075 variant with KASPar SNP
genotyping system (LGC Genomics, Hoddeson, UK) in the Danish cohort, which
comprises data from ﬁve sample sets (Supplementary Note 2 also for the
genotyping and QC analysis for this variant).
We used Cox-proportional hazard regression models to assess the association of
the variant with the risk of incident T2D in 1,652 nondiabetic male subjects
genotyped in the Inter99 cohort (part of the Danish cohort) that were followed for
11 years on average. The follow-up analysis was restricted to male individuals
younger than 45 years who were 56 years old after 11 years of follow-up.
Individuals with self-reported diabetes at the baseline examination and individuals
present in the Danish National diabetes registry before the baseline examination
were also excluded. To include the follow-up study as a part of the replication
cohorts, we used a meta-analysis method that accounts for overlapping samples
(MAOS)66, as we had to control for the sample overlap between the follow-up and
the case-control study from the Danish samples.
See Supplementary Note 2 for a larger description of each of the ﬁve replication
cohorts and how they have been processed.
We meta-analyzed the association results from these ﬁve replication data sets
with the 70KforT2D data sets. In the ﬁnal meta-analysis, we excluded whenever it
was possible (a) controls younger than 55 years and (b) with OGTT > 7.8 mmol l
−1 or with family history of T2D.
In silico functional characterization of rs146662075. This variant is located in
an intergenic region, ﬂanked by AGTR2 and SLC6A14 genes, and within several
DNase I hypersensitive sites. We searched for regulatory marks (i.e., H3K4me1 and
H3K27ac marks) through the HaploReg web server (http://archive.broadinstitute.
org/mammals/haploreg/haploreg.php), in order to assess which type of regulatory
element was associated with the rs146662075 variant.
To further evaluate the putative regulatory role of rs146662075, we used the
WashU EpiGenome Browser (http://epigenomegateway.wustl.edu/browser/, last
access on June 2016). We used the following public data hubs: (1) the reference
human epigenomes from the Roadmap Epigenomics Consortium track hubs and
(2) the Roadmap Epigenomics Integrative Analysis Hub. These data were released
by the NIH Roadmap Epigenomics Mapping Consortium51. RNA-seq data were
used to evaluate whether gene expression of any of the closest genes (AGTR2 and
SLC6A14 genes, ﬁxed scale at 80 RPKM) correlated with the presence of the
H3K27ac enhancer marks (a more strict mark for active enhancers in contrast with
H3K4me167, which were highlighted by the HaploReg search) at the rs146662075
location. For visualizing the H3K27ac marks around rs146662075, we focused on a
region of 8 kb and we used a ﬁxed scale at 40 −log10 Poisson p-value of the counts
relative to the expected background count (λlocal).
The NIH Roadmap Epigenomics Consortium data from standardized
epigenomes also allowed us to further interrogate which target gene within the
same topologically associating domain (TAD) was more likely to be regulated by
this rs146662075 enhancer. We used H3K27ac narrow peaks from 59 tissues called
using MACSv2 with a p-value threshold of 0.01 from 98 consolidated epigenomes
to seek for enhancer marks in a given tissue (the presence of H3K27ac peak). To
assess gene expression for any of the putative target genes within TAD, we used the
RPKM expression matrix for 57 consolidated epigenomes (http://egg2.wustl.edu/
roadmap/data/byDataType/rna/) and gene expression quantiﬁcations for fetal
muscle leg, fetal muscle trunk, and fetal stomach provided by ENCODE (https://
www.encodeproject.org/). With this, we were able to test for each of the genes, the
association between gene expression and enhancer activity in 31 tissues with a
Fisher’s exact test.
Allele-speciﬁc enhancer activity at rs146662075. The mouse C2C12 cell line
(ATCC CRL-1772) was grown in DMEM medium supplemented with 10% FBS
and was induced to differentiate in DMEM with 10% horse serum for 4 days.
The human fetal myoblast cell line was established by Prof. Giulio Cossu
(Institute of Inﬂammation and Repair, University of Manchester)68. The authors
played no role in the procurement of the tissue. Cells were cultured in DMEM
medium supplemented with 10% fetal calf serum and was induced to differentiate
in DMEM with 2% horse serum for 4 days.
To perform an electrophoretic mobility shift assay, nuclear extracts from mouse
myoblast C2C12 cells and the human myoblast cell line (ATCC CRL-1772) were
obtained as described before69. Double-stranded oligonucleotides containing either the
common or rare variants of rs146662075 were labeled using dCTP [α-32P] (Perkin
Elmer). Oligonucleotide sequences are as follows (SNP location is underlined): probe-
C-F: 5′-gatcTTTGAACACcGAGGGGAAAAT-3′ and R:5′-gatcATTTTCCCCTC
gGTGTTCAAA-3′ and probe-T-F: 5′- gatcTTTGAACACtGAGGGGAAAAT-3′ and
R: 5′-gatcATTTTCCCCTCaGTGTTCAAA-3′. Assay speciﬁcity was assessed by
preincubation of nuclear extracts with 50- and 100-fold excess of unlabeled wild-type
or mutant probes, followed by electrophoresis on a 5% nondenaturing polyacrylamide
gel. Findings were conﬁrmed by repeating binding assays on separate days.
For evaluating if the activity of the rs146662075 enhancer was allele speciﬁc, we
performed a luciferase assay. A region of 969 bp surrounding rs146662075 was
ampliﬁed from human genomic DNA using F: 5′-
GCTAGCATATGGAGGTGATTTGT-3′ and R: 5′-
GGCACTTCCTTCTCTGGTAGA-3′ oligonucleotides and cloned into pENTR/D-
TOPO (Invitrogen). Allelic variant rs146662075T was introduced by site-directed
mutagenesis using the following primers: F: 5′-
CCTTTTTTTACTTTGAACACTGAGGGGAAAATCATGCTTGGC-3′ and R: 5′-
GCCAAGCATGATTTTCCCCTCAGTGTTCAAAGTAAAAAAAGG-3′.
Enhancer sequences were shuttled into pGL4.23[luc2/minP] vector (Promega)
adapted for Gateway cloning (pGL4.23-GW, 2) using Gateway LR Clonase II
Enzyme mix (Invitrogen). Correct cloning was conﬁrmed both by Sanger
sequencing and restriction digestion.
C2C12 (ATCC CRL-1772) and 293T (ATCC CRL-3216) cells were transfected
in quadruplicates with 500 ng of pGL4.23-GW enhancer containing vectors and 0.2
ng of Renilla normalizer plasmid. Transfections were carried out in 24-well plates
using Lipofectamine 2000 and Opti-MEM (Thermo Fisher Scientiﬁc) following the
manufacturer’s instructions. Luciferase activity was measured 48 h after
transfection using Dual-Luciferase Reporter Assay System (Promega). Fireﬂy
luciferase activity was normalized to Renilla luciferase activity, and the results were
expressed as a normalized ratio to the empty pGL4.23[luc2/minP] vector backbone.
Experiments were repeated three times. Statistical signiﬁcance was evaluated
through a Student’s t-test.
Data availability. The association results are available at the Type 2 Diabetes
Knowledge portal (www.type2diabetesgenetics.org/) and the complete summary
statistics are available for download at http://cg.bsc.es/70kfort2d/
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